CG Oncology logo

CG Oncology

CGON | NASDAQ
Chart Builder DCF Calculator
$84.78
+$10.38 (+13.95%)
At close: Nov 16, 2026, 4:00 PM ET
$83.89
-$0.89 (-1.04%)
After-hours: Nov 16, 2026, 7:48 PM ET
+13.95%

Rating

Updated: Nov 16, 2026
37.8
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #584/1021 (Top 57%)

Key Statistics

Market Data

Market Cap $7.57B
1D Range
78.27 93.95
52W Range
37.37 93.95

Valuation (TTM)

PE -30.61
PB 7.64
EV/EBITDA -27.34

Valuation (NTM)

Forward PE N/A
Forward PEG -0.70
Price Target $92.50
Loading financial charts...

Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s prod...

Sector Healthcare
Industry Biotechnology
Employees 142
IPO Date Jan 25, 2024
Fiscal Year January - December

Latest News

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds

14 hours ago · benzinga.com

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
2 Cancer-Drug Developers Seeing Unusual Options Volume

14 hours ago · schaeffersresearch.com

2 Cancer-Drug Developers Seeing Unusual Options Volume
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out

16 hours ago · investors.com

CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)

19 hours ago · globenewswire.com

PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates

11 days ago · zacks.com

CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates

11 days ago · globenewswire.com

CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy

21 days ago · seekingalpha.com

CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

1 month ago · globenewswire.com

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

1 month ago · gurufocus.com

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Earnings

Latest Earnings
Nov 6, 2026
EPS
-$0.64
Beat +23.27%
REV
$1.6M
Beat +192.87%
Next Earnings
Feb 26, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$92.50
Upside
+9.11%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.